HC Wainwright Issues Optimistic Estimate for TVRD Earnings

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) – Stock analysts at HC Wainwright raised their Q3 2026 EPS estimates for shares of Tvardi Therapeutics in a report issued on Friday, August 14th. HC Wainwright analyst S. Nik now forecasts that the company will earn ($0.61) per share for the quarter, up from their previous estimate of ($0.86). HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Tvardi Therapeutics’ current full-year earnings is ($2.32) per share. HC Wainwright also issued estimates for Tvardi Therapeutics’ Q4 2026 earnings at ($0.54) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($4.52) EPS and FY2028 earnings at ($6.24) EPS.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04).

A number of other research firms also recently issued reports on TVRD. Piper Sandler upgraded shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a research report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Wednesday, July 8th. Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday, July 8th. UBS Group raised shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective on the stock in a research report on Wednesday, July 8th. Finally, BTIG Research decreased their target price on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tvardi Therapeutics Trading Down 2.1%

Shares of NASDAQ TVRD opened at $1.86 on Tuesday. Tvardi Therapeutics has a one year low of $1.50 and a one year high of $43.65. The business has a 50-day moving average price of $2.47 and a two-hundred day moving average price of $3.16. The firm has a market capitalization of $17.45 million, a PE ratio of -0.67 and a beta of 0.39.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TVRD. Vanguard Group Inc. raised its holdings in Tvardi Therapeutics by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock worth $16,335,000 after acquiring an additional 20,757 shares during the period. American Financial Group Inc. acquired a new position in shares of Tvardi Therapeutics during the 4th quarter worth about $962,000. Vestal Point Capital LP acquired a new position in shares of Tvardi Therapeutics during the 3rd quarter worth about $6,508,000. Geode Capital Management LLC boosted its stake in Tvardi Therapeutics by 6.2% during the 4th quarter. Geode Capital Management LLC now owns 157,133 shares of the company’s stock valued at $676,000 after purchasing an additional 9,214 shares during the period. Finally, State Street Corp grew its holdings in Tvardi Therapeutics by 83.7% in the 4th quarter. State Street Corp now owns 115,501 shares of the company’s stock valued at $497,000 after buying an additional 52,637 shares during the last quarter. 44.66% of the stock is currently owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.